NeuroDerm Ltd. - Ordinary Share (NDRM) Stock Price, News & Analysis

Company Overview

NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Key Stats

• Today's Range: $38.85 to $38.85
• 50-Day Range: N/A
• 52-Week Range: $15.20 to $38.95
• Volume: N/A
• Average Volume: 418,712 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NDRM Stock Analysis - Frequently Asked Questions

How were NeuroDerm Ltd. - Ordinary Share's earnings last quarter?

NeuroDerm Ltd. - Ordinary Share (NASDAQ:NDRM) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.13.

When did NeuroDerm Ltd. - Ordinary Share IPO?

NeuroDerm Ltd. - Ordinary Share (NDRM) raised $45 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 4,500,000 shares at $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

What other stocks do shareholders of NeuroDerm Ltd. - Ordinary Share own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroDerm Ltd. - Ordinary Share investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), (KITE) (KITE) and Dynavax Technologies (DVAX).

Company Calendar

• Last Earnings: 5/11/2017
• Today: 3/19/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NDRM
• CIK: 1598696
• Web: neuroderm.com
• Phone: +972-8-9462729
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A